The stock of Galapagos NV (ADR) (NASDAQ:GLPG) is a huge mover today! About 103,363 shares traded hands. Galapagos NV (ADR) (NASDAQ:GLPG) has risen 48.70% since March 15, 2016 and is uptrending. It has outperformed by 43.22% the S&P500.
The move comes after 5 months positive chart setup for the $2.93B company. It was reported on Oct, 18 by Barchart.com. We have $84.73 PT which if reached, will make NASDAQ:GLPG worth $791.10M more.
Analysts await Galapagos NV (ADR) (NASDAQ:GLPG) to report earnings on November, 11.
Galapagos NV (ADR) (NASDAQ:GLPG) Ratings Coverage
Out of 4 analysts covering Galapagos NV (NASDAQ:GLPG), 2 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 50% are positive. Galapagos NV has been the topic of 5 analyst reports since August 11, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Monday, May 2 by Morgan Stanley. Zacks upgraded it to “Hold” rating and $67 target price in Tuesday, August 11 report. The stock has “Neutral” rating given by Goldman Sachs on Monday, January 25. Janney Capital initiated Galapagos NV (ADR) (NASDAQ:GLPG) on Tuesday, August 30 with “Buy” rating. The firm earned “Neutral” rating on Monday, September 28 by Credit Suisse.
According to Zacks Investment Research, “Galapagos NV is a biotechnology company. The Company’s operating segment consists of Research and Development and Services. Research and Development segment is engaged in the discovery and development of small molecules. Services segment offers drug discovery products and services. Its products include GLPG0634 for the treatment of rheumatoid arthritis and other inflammatory diseases, GLPG1205/GLPG1690 for treating inflammatory bowel disease, GSK2586184 for the treatment of chronic immuno-inflammatory diseases and GLPG0974, to prevent free fatty acid-induced activation and migration of neutrophils which are in different clinical trial. Galapagos NV is headquartered in Mechelen, Belgium.”
More important recent Galapagos NV (ADR) (NASDAQ:GLPG) news were published by: Marketwatch.com which released: “/quotes/zigman/3870025/realtime” on September 22, 2011, also Quotes.Wsj.com published article titled: “DOW JONES, A NEWS CORP COMPANY”, Businessfinancenews.com published: “Galapagos NV, Gilead Sciences Together to Fight Against Rheumatoid Arthritis” on December 17, 2015. More interesting news about Galapagos NV (ADR) (NASDAQ:GLPG) was released by: Benzinga.com and their article: “IPO Outlook: Galapagos Offers New Hope For CF And RA Sufferers” with publication date: May 12, 2015.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.